GPCRs: Uncovering Novel Targets for Drug Discovery
European GPCR Technology Symposium Presented by DiscoverX and GDR-3545
Date: April 12, 2016
Time: 09:00 AM – 5:00 PM
Location: The MacGrath Lecture Theatre, St. Catherine’s College, Cambridge, CB2 1RL
This is a FREE symposium!
View the program and register here
Symposium Program
The Apelin and Elabela/Toddler Receptor as Novel Target in Cardiovascular Disease
Anthony Davenport, University of Cambridge
Exploring GPCR Activation in Immunometabolism and Inflammation
David R. Greaves, Professor of Inflammation Biology, University of Oxford
Fluorescent Probes to Track GPCR Binding and Dimerization
Dominique Bonnet, CNRS researcher, University of Strasbourg
Natural Biased-ligands: A Classical Tine-tuner of GPCR Physiology? Example of the Renin-Angiotensin-Aldosterone System
Céline GALES, Université Paul Sabatier, Toulouse, France
Allosteric Regulation of TGFß Type I Receptor by the Orphan GPR50 – an Alternative Way to Define the Function of Orphan GPCRs
Ralf Jockers, Institut Cochin, Paris, Inserm U1016, CNRS 8104, Université Paris Descartes
From Receptors to Ligands: Evotec’s Integrated Pipeline for GPCR Structure-Based Drug Discovery
Dr Constantino Diaz, Evotec (France) SAS
Linking the Mast Cell Receptor, Mrgprx2, to Adverse Histamine-like Reactions in vivo, in Preclinical Drug Development
Andrew Brown, GSK, Molecular Discovery Research
Using Phenotypic Assays to Explore EP4 Receptor Agonism in Airway Remodeling
Dr Elizabeth M Rosethorne, Snr Research Fellow, University of Nottingham
Identification of Endogenous and Surrogate Ligands for Orphan GPCRs – Through Computational Drug Design Methods
David Gloriam, Associate Professor, Department of Drug Design and Pharmacology, University of Copenhagen